These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1757 related articles for article (PubMed ID: 35218866)
1. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related]
2. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
3. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252 [TBL] [Abstract][Full Text] [Related]
4. Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain. Anzai I; Fujita J; Ono C; Kosaka Y; Miyamoto Y; Shichinohe S; Takada K; Torii S; Taguwa S; Suzuki K; Makino F; Kajita T; Inoue T; Namba K; Watanabe T; Matsuura Y Microbiol Spectr; 2024 Apr; 12(4):e0365523. PubMed ID: 38415660 [TBL] [Abstract][Full Text] [Related]
5. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity. Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q Front Immunol; 2022; 13():1041860. PubMed ID: 36532082 [TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP mBio; 2021 Mar; 12(2):. PubMed ID: 33785634 [TBL] [Abstract][Full Text] [Related]
7. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480 [TBL] [Abstract][Full Text] [Related]
8. The SpACE-CCM: A facile and versatile cell culture medium-based biosensor for detection of SARS-CoV-2 spike-ACE2 interaction. Ham Y; Cho NC; Kim D; Kim JH; Jo MJ; Jeong MS; Pak BY; Lee S; Lee MK; Chi SW; Kim TD; Jeong NC; Cho S Biosens Bioelectron; 2023 May; 227():115169. PubMed ID: 36827795 [TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction. Eka Saputri M; Aisyah Rahmalia Effendi S; Nadila R; Azzam Fajar S; Damajanti Soejoedono R; Handharyani E; Nadia Poetri O Int Immunopharmacol; 2022 Nov; 112():109280. PubMed ID: 36183680 [TBL] [Abstract][Full Text] [Related]
11. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR Front Immunol; 2021; 12():691715. PubMed ID: 34149735 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. Walker SN; Chokkalingam N; Reuschel EL; Purwar M; Xu Z; Gary EN; Kim KY; Helble M; Schultheis K; Walters J; Ramos S; Muthumani K; Smith TRF; Broderick KE; Tebas P; Patel A; Weiner DB; Kulp DW J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32855181 [No Abstract] [Full Text] [Related]
13. A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. Alves J; Engel L; de Vasconcelos Cabral R; Rodrigues EL; de Jesus Ribeiro L; Higa LM; da Costa Ferreira Júnior O; Castiñeiras TMPP; de Carvalho Leitão I; Tanuri A; Goueli SA; Zegzouti H Sci Rep; 2021 Sep; 11(1):18428. PubMed ID: 34531417 [TBL] [Abstract][Full Text] [Related]
14. Liposome-based high-throughput and point-of-care assays toward the quick, simple, and sensitive detection of neutralizing antibodies against SARS-CoV-2 in patient sera. Streif S; Neckermann P; Spitzenberg C; Weiss K; Hoecherl K; Kulikowski K; Hahner S; Noelting C; Einhauser S; Peterhoff D; Asam C; Wagner R; Baeumner AJ Anal Bioanal Chem; 2023 Mar; 415(8):1421-1435. PubMed ID: 36754874 [TBL] [Abstract][Full Text] [Related]
15. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802 [TBL] [Abstract][Full Text] [Related]
16. Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants. Li B; Zhao Y; Wu X; Wu H; Tang W; Yu X; Mou J; Tan W; Jin M; Li W; Zhang Q; Liu M ACS Nano; 2023 Apr; 17(7):7017-7034. PubMed ID: 36971310 [TBL] [Abstract][Full Text] [Related]
17. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine. Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669 [TBL] [Abstract][Full Text] [Related]
18. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109 [TBL] [Abstract][Full Text] [Related]
19. Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization. Byazrova M; Gattinger P; Astakhova E; Hofer G; Khaitov M; Filatov A; Valenta R Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982183 [TBL] [Abstract][Full Text] [Related]
20. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]